Tous Actualités
Suivre
Abonner Grünenthal GmbH

Grünenthal GmbH

Grünenthal GmbH presents tapentadol, a novel centrally acting analgesic, at the 25th Annual Scientific Meeting of The American Pain Society

Aachen (ots)

Tapentadol would be the first new molecular entity
in the class of oral centrally acting analgesics to enter medical
practice in over 25 years.
At the American Pain Society Meeting in San Antonio, Texas,
Grünenthal GmbH presented positive results on preclinical and early
clinical studies of tapentadol (CG5503 / R331333).
Tapentadol is a novel centrally acting analgesic with a dual mode
of action suited for the treatment of moderate-to-severe pain.
"According to the latest study results tapentadol demonstrates the
efficacy of a strong centrally acting analgesic with markedly
improved gastro-intestinal tolerability compared to standard opioid
analgesics", explains Anton Hoos, MD, Vice President Global
Development at Grünenthal. "At dosages with a comparable efficacy to
morphine, tapentadol showed significantly less incidences of nausea
and vomiting, side effects which often limit the use of opioids in
pain patients", he continued. "The data indicate that tapentadol has
the potential to offer substantial benefits to pain patients by
providing an excellent balance between efficacy and tolerability",
commented Teun Grooters, MD, Vice President Global Marketing,
Grünenthal.
This new strong analgesic is the latest innovation coming out of
Grünenthal's R&D pipeline. It adds to the portfolio of pain products
developed and marketed by Grünenthal, whose prime aim is to help
physicians to improve pain management and patient care.
Grünenthal entered into a licensing agreement for tapentadol with
Ortho-McNeil Pharmaceutical in February 2003. Under the agreement,
Grünenthal is co-developing the product with Johnson & Johnson
Pharmaceutical Research & Development, L.L.C. (J&JPRD). Both
Ortho-McNeil Pharmaceutical and J&JPRD are affiliates of Johnson &
Johnson. Phase III studies will commence later this year. Upon
successful completion of the phase III studies and regulatory
approval tapentadol would be the first new molecular entity in its
class to enter medical practice in more than 25 years.
About APS - American Pain Society and the 25th Annual Scientific
   Meeting
The American Pain Society is a multidisciplinary organization of
basic and clinical scientists, practicing clinicians, policy
analysts, and others. The mission of the American Pain Society is to
advance pain-related research, education, treatment and professional
practice. The 25th Annual Meeting of the society took place in San
Antonio, Texas, USA from May 3 to 6, 2006. It was attended by almost
2000 participants, mainly from the USA.
About Grünenthal
Grünenthal researchs, develops and produces high therapeutic value
medicines and markets them throughout the world. Grünenthal is an
expert in drugs for pain therapy and gynaecology and a leader in the
field of intelligent, user-friendly drug delivery technologies.
Grünenthal is an independent, family-owned company with a long
history of international cooperations. The company was founded in
1946 and has its headquarters in Germany. We supply our markets from
seven production sites around the world and have affiliates in 26
countries. Grünenthal employs about 1,800 people in Germany and about
4,800 world-wide. Sales in 2005 amounted to approximately 780 million
Euros.
ots Orginaltext: Grünenthal GmbH
Internet: www.presseportal.ch

Contact:

Grünenthal GmbH
Anke Krüger-Hellwig
52099 Aachen, Germany
Phone: +49 241 569-2858
Fax: +49 241 569-1486,
E-Mail: anke.krueger-hellwig@grunenthal.com
Internet: www.grunenthal.com